On Wednesday, Stifel analysts maintained a Buy rating on shares of Denali Therapeutics Inc. (NASDAQ:DNLI) with a price target of $37.00. According to InvestingPro data, analysts remain highly bullish on the stock, with a consensus "Strong Buy" rating and price targets ranging from $24 to $87.
The firm's endorsement comes after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to Denali's DNL310 for the treatment of Hunter Syndrome. The analysts highlighted the significance of this development, noting that the company is on track to file a Biologics License Application (BLA) for accelerated approval early in 2025.
While the company currently shows negative earnings with an EBITDA of -$512 million, InvestingPro analysis indicates the stock is currently trading below its Fair Value, suggesting potential upside opportunity for investors.
The FDA's decision is seen as a validation of the compelling nature of Denali's data and the potential of DNL310 to be a leading treatment in its class. Stifel's analysis suggests that the BTD could reduce the risk associated with the drug's approval process and has positive implications for Denali's other enzyme replacement therapy, DNL126, which is being developed for Sanfilippo Syndrome.
The analysts emphasized that although DNL310 will require a confirmatory study after the potential accelerated approval, which might be necessary to mitigate the risk outside the U.S., the progress towards accelerated approval further supports the credibility of Denali's blood-brain barrier platform.
The market opportunities for treating Hunter Syndrome and Sanfilippo Syndrome combined are estimated to exceed $1 billion. The company maintains a strong financial position with a current ratio of 9.98 and minimal debt-to-equity of 0.04, providing ample resources for continued development.
Stifel's continued support for Denali Therapeutics stock follows a recent decline in share value after the failure of another drug candidate, eIF2B, which the analysts considered high-risk and not central to their investment thesis.
The firm remains optimistic about the stock's risk/reward profile in the wake of this recent development. For deeper insights into Denali's financial health and additional analyst perspectives, investors can access over 30 key metrics and exclusive analysis through InvestingPro.
In other recent news, Denali Therapeutics has seen significant developments in its clinical trials and analyst ratings. The U.S. Food and Drug Administration (FDA) awarded Breakthrough Therapy Designation to Denali's investigational drug tividenofusp alfa, intended for the treatment of Hunter syndrome.
This recognition is expected to expedite the review process for the drug, which has shown promise in early clinical trials. Denali plans to submit a Biologics License Application for tividenofusp alfa early this year, seeking accelerated approval.
In addition, Denali's Phase II/III HEALEY trial for ALS treatment DNL343 did not meet its primary endpoint, though the treatment was deemed safe and well-tolerated. This led to various responses from analysts, with H.C. Wainwright and BofA Securities reducing their price targets for Denali, while maintaining a Buy rating. Baird initiated coverage on Denali with an Outperform rating and set a price target of $31.00.
Furthermore, Jefferies maintained a Buy rating on Denali Therapeutics, highlighting potential Hunter Syndrome approval in 2025. Despite recent trial results, analysts from BofA Securities and Baird remain optimistic about Denali's prospects, particularly due to its Transport Vesicle platform and the promising prospects of Tividenofusp alfa. These are recent developments in the company's trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.